
PaweÅ, MoÄ**‡**o

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5877575/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatology International, 2018, 38, 189-201.	3.0	45
2	Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis. Pharmacological Reports, 2016, 68, 1237-1243.	3.3	28
3	The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 759-786.	1.4	21
4	An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients. Journal of Comparative Effectiveness Research, 2018, 7, 101-111.	1.4	18
5	Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. Pharmacotherapy, 2016, 36, 870-879.	2.6	17
6	Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis. Journal of Comparative Effectiveness Research, 2017, 6, 601-612.	1.4	14
7	Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Clinical Drug Investigation, 2017, 37, 25-37.	2.2	14
8	Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis. Archives of Medical Science, 2016, 5, 1088-1096.	0.9	12
9	Indirect costs of absenteeism due to rheumatoid arthritis, psoriasis, multiple sclerosis, insulin-dependent diabetes mellitus, and ulcerative colitis in 2012: a study based on real-life data from the Social Insurance Institution in Poland. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 295-303.	1.4	9
10	Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes. Public Health, 2017, 145, 51-58.	2.9	4
11	The Indirect Costs of Multiple Sclerosis Associated With Absenteeism In Poland. Value in Health, 2014, 17, A528-A529.	0.3	1
12	The Indirect Costs of Inflammatory Bowel Disease (Crohn's Disease And Ulcerative Colitis) Associated With Absenteeism In Poland In 2013. Value in Health, 2015, 18, A665.	0.3	0
13	The Indirect Costs of Multiple Sclerosis Associated With Absenteeism In Poland In 2013. Value in Health, 2015, 18, A754.	0.3	0
14	The Indirect Costs of Types 1 Diabetes Mellitus Associated with Absenteeism in Poland in 2013. Value in Health, 2015, 18, A603.	0.3	0
15	Does Real World Evidence Support Conclusions From Experimental Evidence In Decision-Making Processes In Poland?. Value in Health, 2016, 19, A449.	0.3	Ο